S100A9 is Involved in Hepatitis B Virus X-induced Proliferation and Migration of Human Hepatocellular Carcinoma Cell HepG2

doi:10.13523/j.cb.20181001

China Biotechnology

2018, Vol. 38

Issue (10): 1-7 DOI: 10.13523/j.cb.20181001

Orginal Article

S100A9 is Involved in Hepatitis B Virus X-induced Proliferation and Migration of Human Hepatocellular Carcinoma Cell HepG2

Xiu-yu ZHANG¹,Ding WANG¹,Yan-e DU¹,Rui WU²,Liang DUAN^1,^**(

)

1 The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
2 The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

Download:

HTML

PDF(1365KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Objective: To investigate the effect of S100A9 on hepatocellular carcinoma cell HepG2 and the relevant mechanism.Methods: CCK-8 assay and cell migration assay were used to study HepG2 growth and migration mediated by Hepatitis B virus X (HBx) respectively. Transfected S100A9-siRNA into cells for silencing S100A9 expression, then the growth and migration of HepG2 infected with AdHBx were analyzed. Real-time PCR and Western blot were used to detect S100A9 mRNA levels and expression in HepG2 cells infected with AdHBx or AdGFP. After the treatment with or without NF-κB inhibitor BAY11-7082, S100A9 mRNA levels and expression in AdHBx-infected HepG2 cells were detected again.Result: HBx enhances the growth and migration of HepG2 cells. Silencing S100A9 expression partially blocked HBx-induced growth and migration of HepG2 cells. The mRNA level and protein expression of S100A9 were significantly higher in HepG2 cells infected with AdHBx than with AdGFP, and that suggests S100A9 expression can be modulated by HBx. NF-κB inhibitor treatment efficiently suppressed the increase of S100A9 levels caused by HBx.Conclusion: Expression of S100A9 is regulated by HBx-mediated NF-κB activation, and S100A9 plays an important role in HBx-induced growth and migration of hepatocellular carcinoma cell HepG2.

Key words： S100A9 HepG2 cells Hepatitis B virus X NF-kappa B

Received: 19 June 2018 Published: 09 November 2018

ZTFLH:

R73

Corresponding Authors: Liang DUAN E-mail: dl13640529186@gmail.com

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Xiu-yu ZHANG
	Ding WANG
	Yan-e DU
	Rui WU
	Liang DUAN

Cite this article:

Xiu-yu ZHANG,Ding WANG,Yan-e DU,Rui WU,Liang DUAN. S100A9 is Involved in Hepatitis B Virus X-induced Proliferation and Migration of Human Hepatocellular Carcinoma Cell HepG2. China Biotechnology, 2018, 38(10): 1-7.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20181001 OR https://manu60.magtech.com.cn/biotech/Y2018/V38/I10/1

Fig.1 Identification of HBx expression in HepG2 cells infected with AdHBx (a) Fluorescence microscope observation of HepG2 cells after being infected with AdHBx(50×) (b) HBx expression in HepG2 cells infected with AdHBx or AdGFP

Fig.2 Effect of HBx on proliferation (a) and migration (b) (c) of HepG2 cells ^** P<0.01, ^*** P<0.001 compared with HepG2 cells infected with AdHBx

Fig.3 S100A9-siRNA reduced the promoting effect of HBx on proliferation (a) and migration (b) (c) of HepG2 cells ^* P<0.05, ^** P<0.01, ^*** P<0.001 compared with HepG2/AdHBx cells transfected with S100A9-siRNA

Fig.4 S100A9 expression in HepG2/ AdHBx cells and HepG2/ AdGFP (a) Real time PCR (b) Western blot ^*** P<0.001 compared with HepG2/AdGFP cells

Fig.5 Blocking NF-κB transcriptional activity can suppresse S100A9 expression (a) Dual luciferase reporter assay analysis for the effect of HBx on NF-κB transcriptional activity (b) Real time PCR analysis for S100A9 mRNA level in HepG2/ AdHBx cells received treatment with BAY11-7082 (c) Western blot analysis for S100A9 expression in HepG2/ AdHBx cells received treatment with BAY11-7082 ^** P<0.01, ^*** P<0.001 compared with HepG2/AdHBx cells transfected with BAY11-7082


[1]	Zhu R X, Seto W K, Lai C L , et al. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver, 2016,10(3):332-339. doi: 10.5009/gnl15257 pmid: 27114433

[2]	Levrero M, Zucman-Rossi J . Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol, 2016,64(1 Suppl):S84-S101. doi: 10.1016/j.jhep.2016.02.021

[3]	Seeger C, Mason W S . Molecular biology of hepatitis B virus infection. Virology, 2015, 479-480:672-686. doi: 10.1016/j.virol.2015.02.031 pmid: 25759099

[4]	Zhang X D, Wang Y, Ye L H . Hepatitis B virus X protein accelerates the development of hepatoma. Cancer Biol Med, 2014,11(3):182-190. doi: 10.7497/j.issn.2095-3941.2014.03.004 pmid: 4197427

[5]	Sung W K, Zheng H, Li S , et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet, 2012,44(7):765-769. doi: 10.1038/ng.2295 pmid: 22634754

[6]	Bianchi M E . DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol, 2007,81(1):1-5. doi: 10.1189/jlb.0306164 pmid: 17032697

[7]	Chen H, Xu C, Jin Q , et al. S100 protein family in human cancer. AM J Cancer Res, 2014,4(2):89-115. doi: 10.3901/JME.2014.16.089 pmid: 3960449

[8]	Markowitz J , Iii W E C. Review of S100A9 biology and its role in cancer. Biochim Biophys Acta, 2013,1835(1):100-109. doi: 10.1016/j.bbcan.2012.10.003 pmid: 3670606

[9]	Motavaf M, Safari S, Saffari J M , et al. Hepatitis B virus-induced hepatocellular carcinoma: the role of the virus x protein. Acta Virol, 2013,57(4):389-396. doi: 10.4149/av_2013_04_389 pmid: 24294951

[10]	Zhang T, Zhang J, You X , et al. Hepatitis B virus X protein modulates oncogene yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology, 2012,56(6):2051-2059. doi: 10.1002/hep.25899 pmid: 22707013

[11]	Chen Z, Tang J, Cai X , et al. HBx mutations promote hepatoma cell migration through the Wnt/β-catenin signaling pathway. Cancer Sci, 2016,107(10):1380-1389. doi: 10.1111/cas.13014 pmid: 27420729

[12]	Chen B, Miller A L, Rebelatto M , et al. S100A9 induced inflammatory responses are mediated by distinct damage associated molecular patterns (DAMP) receptors in vitro and in vivo. PLoS One, 2015,10(2):e0115828. doi: 10.1371/journal.pone.0115828 pmid: 25706559

[13]	van Lent P L, Grevers L, Blom A B , et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis, 2008,67(12):1750-1758. doi: 10.1136/ard.2007.077800

[14]	Lee M J, Lee J K, Choi J W , et al. Interleukin-6 induces S100A9 expression in colonic epithelial cells through STAT3 activation in experimental ulcerative colitis. PLoS One, 2012,7(9):e38801. doi: 10.1371/journal.pone.0038801 pmid: 22962574

[15]	Tsai S Y, Seqovia J A, Chang T H , et al. DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza a virus infection: role of DDX21-TRIF-TLR4-MyD88 pathway. PloS Pathog, 2014,10(1):e1003848. doi: 10.1371/journal.ppat.1003848 pmid: 3879357

[16]	Baines K J, Hsu A C, Tooze M , et al. Novel immune genes associated with excessive inflammatory and antiviral responses to rhinovirus in COPD. Respir Res, 2013,14(1):15. doi: 10.1186/1465-9921-14-15 pmid: 23384071

[17]	Gebhardt C, Nemeth J, Angel P , et al. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol, 2006,72(11):1622-1631. doi: 10.1016/j.bcp.2006.05.017 pmid: 16846592

[18]	Srikrishna G . S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun, 2012,4(1):31-40. doi: 10.1159/000330095

[19]	Wu R, Duan L, Cui F , et al. S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1 /2 and p38 MAPK pathways. Exp Cell Res, 2015,334(2):228-238. doi: 10.1016/j.yexcr.2015.04.008 pmid: 25907296

[20]	Hermani A, Hess J, De Servi B , et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res, 2005,11(14):5146-5152. doi: 10.1158/1078-0432.CCR-05-0352 pmid: 16033829

[21]	Kim H J, Kang H J, Lee H , et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res, 2009,8(3):1368-1379. doi: 10.1021/pr8007573 pmid: 19186948

[22]	Nemeth J, Stein I, Haag D , et al. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver arcinogenesis. Hepatology, 2009,50(4):1251-1262. doi: 10.1002/hep.23099

[1]	HU Li-jun,DUAN Liang,HUANG Yi-yun,LIN Lu,HUANG Mao,CHEN Lu,PENG Qi,HU Qin,ZHANG Yan,ZHOU Lan. *S100A9 Is Involved in Fusobacterium nucleatum-Induced Proliferation and Migration of Colon Cancer HCT116 and SW480 Cells*[J]. China Biotechnology, 2020, 40(1-2): 84-91.

[2]	WU Rui, ZHOU Lan, CUI Fang. S100A9 Promotes Human Hepatocellular Carcinoma Cell HepG2 Proliferation and Invasion Involving RAGE[J]. China Biotechnology, 2015, 35(5): 8-14.

[3]	LIANG Li-zhu, SUN Jia-nan, LI Kai, LIU Ming-wei, DING Chen, QIN Jun. Proteome-wide Screening of Transcription Factor DNA Binding Activity in HepG2 Cells after Oleic Acid Treatment[J]. China Biotechnology, 2015, 35(5): 22-31.

[4]	SONG Ming-li, LIN Yu, LUO Nan-shu, FENG Quan-yi, HUANG Qi-ping, ZHANG Hwan-you, ZHANG Yi-guo, WU Ze-zhi. Enhancement of the Expression and Responsiveness of TRPV1 and TRPV4 Channels on HepG2 Cells with Micropillar Arrayed Substrate Topography[J]. China Biotechnology, 2015, 35(10): 1-12.

[5]	ZHU Xiao-san, DAI Yi-chen, CHEN Zhang-xing, XIE Jun-pei, ZENG Wei, LIN Yuan-yuan, ZHAO Ben-hua. ECHS1 Involved in Antagonising Apoptosis in HepG2 Cells via the Mitochondrial Pathway[J]. China Biotechnology, 2013, 33(8): 11-16.

[6]	ZHANG Yang-de, DUAN Jing-hua, CHEN Yu-xiang, LIAO Ming-mei, HUANG Bo-yun, ZHAO Jin-feng. Antiproliferative Effect of a Novel Cationic Nanocurcumin on Human Hepatocellular Carcinoma of HepG2 Cells[J]. China Biotechnology, 2010, 30(12): 30-35.

Viewed

Full text

Abstract

Cited

Shared

Discussed